Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03617328
Title Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma (Mel-65)
Acronym Mel-65
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Craig L Slingluff, Jr
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.